---

---

Neoplasia in 4 Hours - Study Plan & Mind Map

Time Allocation (4 hours = 240 min)

---

MIND MAP: NEOPLASIA (Robbins Chapter 6)

NEOPLASIA
│
├── 1. NOMENCLATURE
│   ├── Benign: tissue + "-oma" (Fibroma, Lipoma, Adenoma)
│   ├── Malignant epithelial = Carcinoma (Adeno-, Squamous cell, Basal cell)
│   ├── Malignant mesenchymal = Sarcoma (Fibro-, Lipo-, Osteo-)
│   ├── Mixed tumors: Pleomorphic adenoma, Fibroadenoma, Teratoma
│   ├── Eponyms: Wilms tumor, Ewing sarcoma, Hodgkin lymphoma
│   └── Hamartoma vs Choristoma (know the difference!)
│
├── 2. BENIGN vs MALIGNANT CHARACTERISTICS
│   ├── Differentiation & Anaplasia
│   │   ├── Well differentiated → resembles parent tissue
│   │   ├── Anaplastic = undifferentiated = reliably malignant
│   │   └── Features: pleomorphism, hyperchromatism, high N:C ratio,
│   │       tumor giant cells, atypical mitoses
│   ├── Rate of Growth
│   │   └── Malignant generally grows faster; exceptions exist
│   ├── Local Invasion
│   │   ├── Benign: capsule present, non-invasive
│   │   └── Malignant: no capsule, infiltrates, "crab-like"
│   └── Metastasis (most reliable sign of malignancy)
│       ├── Pathways: Lymphatic (carcinomas) | Hematogenous (sarcomas)
│       │   | Seeding (colon, ovary → peritoneum)
│       └── Common sites: Liver, Lung, Brain, Bone, Adrenal
│
├── 3. EPIDEMIOLOGY
│   ├── Cancer Incidence: Most common in USA - Prostate/Lung/Colon (M), Breast/Lung/Colon (F)
│   ├── Environmental Factors: 80-90% cancers are environmental
│   │   └── Tobacco = #1 avoidable cause
│   ├── Age: Most cancers 55-75 yrs; exceptions: leukemia, Wilms, retinoblastoma (pediatric)
│   └── Acquired Predisposing Conditions
│       ├── Chronic inflammation → Barrett's, chronic gastritis, UC
│       ├── Immunodeficiency → lymphomas, Kaposi sarcoma
│       └── Precancerous lesions: cervical dysplasia, colon polyps, oral leukoplakia
│
├── 4. CANCER GENES
│   ├── Proto-oncogenes → Oncogenes (gain of function, dominant)
│   │   ├── Growth Factors: PDGF (astrocytoma), TGF-α
│   │   ├── Growth Factor Receptors: ERBB2/HER2 (breast), RET (MEN2)
│   │   ├── Signal Transducers: RAS (most common oncogene - 30% all cancers)
│   │   │   └── RAS: KRAS (colon, lung, pancreas), NRAS, HRAS
│   │   ├── Nuclear Transcription Factors: MYC (Burkitt lymphoma t8;14)
│   │   └── Cell Cycle: Cyclin D1 (mantle cell lymphoma)
│   │
│   ├── Tumor Suppressor Genes (loss of function, recessive - Knudson 2-hit)
│   │   ├── RB (Retinoblastoma gene) - "Governor of Cell Cycle"
│   │   │   ├── pRB blocks G1→S by binding E2F
│   │   │   └── Mutated in retinoblastoma, osteosarcoma, small cell lung Ca
│   │   ├── TP53 - "Guardian of the Genome" (most common cancer mutation)
│   │   │   ├── Normally: activates p21 → cell cycle arrest; Bax → apoptosis
│   │   │   ├── Mutated in 70% cancers; Li-Fraumeni syndrome (germline)
│   │   │   └── MDM2 degrades p53 (negative feedback)
│   │   ├── APC/β-catenin (colon cancer - FAP syndrome)
│   │   ├── BRCA1/BRCA2 (breast/ovarian cancer, DNA repair)
│   │   ├── VHL (clear cell RCC - HIF stabilization → VEGF ↑)
│   │   ├── NF1, NF2 (neurofibromatosis)
│   │   └── PTEN, SMAD2/4, E-cadherin
│   │
│   └── Genetic Lesion Types
│       ├── Point mutations: RAS (substitution)
│       ├── Translocations: MYC (Burkitt), BCR-ABL (CML t9;22 Philadelphia)
│       │   BCL2 (follicular lymphoma t14;18)
│       ├── Gene Amplifications: HER2 (breast), NMYC (neuroblastoma), DHFR
│       ├── Deletions: RB, TP53, CDKN2A
│       ├── MicroRNAs: miR-17-92 cluster (oncomiR), miR-15/16 deleted in CLL
│       └── Epigenetic: hypermethylation of TSGs, global hypomethylation
│
├── 5. HALLMARKS OF CANCER (Hanahan & Weinberg - 8 hallmarks)
│   │
│   ├── 1. SELF-SUFFICIENCY IN GROWTH SIGNALS
│   │   ├── Autocrine stimulation (PDGF, TGF-α)
│   │   └── Constitutive activation: RAS mutations, EGFR overexpression
│   │
│   ├── 2. INSENSITIVITY TO GROWTH INHIBITORY SIGNALS
│   │   ├── Loss of RB → uncontrolled E2F activation → S phase entry
│   │   └── TGF-β pathway loss (SMAD mutations)
│   │
│   ├── 3. ALTERED CELLULAR METABOLISM (Warburg Effect)
│   │   ├── Aerobic glycolysis even in O2 → lactate production
│   │   ├── Reason: biosynthetic intermediates for cell growth
│   │   ├── Autophagy: recycling of organelles (pro-survival in starved tumor)
│   │   └── Oncometabolism: IDH1/2 mutations → 2-HG (glioma, AML)
│   │
│   ├── 4. EVASION OF CELL DEATH
│   │   ├── BCL2 overexpression → inhibits apoptosis (t14;18, follicular lymphoma)
│   │   ├── Loss of TP53 → impaired BAX/PUMA pathway
│   │   └── IAP family overexpression
│   │
│   ├── 5. LIMITLESS REPLICATIVE POTENTIAL (Immortality)
│   │   ├── Normal cells: 60-70 doublings → Hayflick limit
│   │   ├── Telomere shortening → senescence/crisis
│   │   └── Telomerase reactivation in cancer → immortality
│   │
│   ├── 6. SUSTAINED ANGIOGENESIS
│   │   ├── VEGF (key pro-angiogenic; target of bevacizumab)
│   │   ├── bFGF
│   │   └── Tumor vessels: leaky, abnormal, hypoxia → HIF-1α → VEGF
│   │
│   ├── 7. INVASION AND METASTASIS
│   │   ├── EMT (Epithelial-Mesenchymal Transition): E-cadherin↓, vimentin↑
│   │   ├── Basement membrane degradation: MMPs (matrix metalloproteinases)
│   │   ├── Steps: Local invasion → intravasation → survival in blood →
│   │   │   extravasation → micrometastasis → colonization
│   │   └── Seed and soil hypothesis (Paget): tumor cell affinity for specific organs
│   │
│   └── 8. EVASION OF IMMUNE SURVEILLANCE
│       ├── Tumor Antigens: Products of mutated genes, overexpressed proteins,
│       │   oncofetal antigens (CEA, AFP), viral antigens (EBV, HPV)
│       ├── Anti-tumor immunity: CD8+ CTLs are key effectors
│       └── Immune evasion: PD-L1 ↑ (checkpoint), MHC-I loss, TGF-β secretion
│           → Basis for PD-1/PD-L1 inhibitor immunotherapy
│
├── 6. CARCINOGENESIS - MULTISTEP
│   ├── Initiation → Promotion → Progression
│   │
│   ├── CHEMICAL CARCINOGENS
│   │   ├── Direct-acting (no metabolism needed): alkylating agents
│   │   ├── Indirect-acting (procarcinogens → activated by CYP450):
│   │   │   Polycyclic hydrocarbons (smoke), Aflatoxin B1 (HCC, mutates TP53),
│   │   │   Nitrosamines (stomach), Vinyl chloride (angiosarcoma liver),
│   │   │   Azo dyes (bladder)
│   │   ├── β-naphthylamine → bladder carcinoma
│   │   └── Asbestos → mesothelioma + lung cancer (synergy with smoking)
│   │
│   ├── RADIATION CARCINOGENESIS
│   │   ├── UV radiation: C→T transitions at pyrimidine dimers → skin cancer
│   │   │   (basal cell, squamous cell, melanoma)
│   │   ├── Ionizing radiation: leukemia, thyroid Ca, breast Ca
│   │   └── Radium → osteosarcoma (historical - dial painters)
│   │
│   └── MICROBIAL CARCINOGENESIS
│       ├── Oncogenic Viruses (DNA):
│       │   ├── HPV 16, 18 → cervical, oropharyngeal Ca (E6 inactivates p53;
│       │   │   E7 inactivates RB)
│       │   ├── EBV → Burkitt lymphoma, Hodgkin, nasopharyngeal Ca
│       │   ├── HBV/HCV → Hepatocellular carcinoma
│       │   ├── HHV-8 (KSHV) → Kaposi sarcoma
│       │   └── Merkel cell polyomavirus → Merkel cell carcinoma
│       ├── Oncogenic Viruses (RNA/Retrovirus):
│       │   └── HTLV-1 → Adult T-cell leukemia/lymphoma
│       └── Bacteria:
│           └── H. pylori → gastric adenocarcinoma + MALT lymphoma
│
└── 7. CLINICAL ASPECTS
    ├── Effects of Tumor on Host
    │   ├── Location effects: pituitary adenoma → hypopituitarism
    │   ├── Functional effects: insulin-secreting islet tumor → hypoglycemia
    │   └── Hemorrhage, infection, rupture
    │
    ├── CANCER CACHEXIA
    │   ├── Profound wasting: loss of fat + muscle
    │   ├── Mediators: TNF-α, IL-1, IL-6, IFN-γ, PIF (proteolysis-inducing factor)
    │   └── Not due to nutritional demand of tumor alone
    │
    ├── PARANEOPLASTIC SYNDROMES (10% patients)
    │   ├── Endocrinopathies:
    │   │   ├── Cushing syndrome: ACTH (small cell lung Ca)
    │   │   ├── SIADH: ADH (small cell lung Ca)
    │   │   ├── Hypercalcemia: PTHrP (squamous cell lung, RCC, breast)
    │   │   └── Hypoglycemia: IGF-2 (mesenchymal tumors, hepatomas)
    │   ├── Nerve/Muscle: Lambert-Eaton (small cell lung - anti-VGCC)
    │   ├── Coagulation: Trousseau syndrome (migratory thrombophlebitis -
    │   │   pancreatic, lung Ca)
    │   └── Hematologic: Polycythemia (RCC, HCC - EPO), Pure red cell aplasia
    │
    ├── GRADING vs STAGING
    │   ├── GRADING: histologic differentiation (I-IV) - microscopic
    │   │   └── Based on differentiation & mitotic index
    │   └── STAGING: clinical/pathologic extent of spread - macroscopic
    │       ├── TNM system (T=tumor size, N=nodes, M=metastasis)
    │       └── More useful for prognosis than grading
    │
    └── TUMOR MARKERS (lab diagnosis)
        ├── PSA (prostate)
        ├── AFP (HCC, yolk sac tumor)
        ├── β-hCG (choriocarcinoma, testicular)
        ├── CEA (colon, pancreas, lung, breast)
        ├── CA-125 (ovary)
        ├── CA 19-9 (pancreas, biliary)
        ├── Calcitonin (medullary thyroid Ca)
        └── TRAP (tartrate-resistant acid phosphatase - hairy cell leukemia)

---

How to Proceed: Robbins + Marrow Strategy

Phase 1 - Robbins Read (First 2.5 hours)

• Read thoroughly (deep reading): Hallmarks of Cancer, Tumor Suppressor genes (RB + p53), Metastasis mechanism, Carcinogens
• Read fast (skim + diagrams only): Epidemiology tables, Nomenclature tables (you'll memorize the logic, not every entry)
• Anchor to diagrams: Robbins has excellent diagrams for RB pathway, p53 pathway, and metastasis cascade - spend 2-3 min per diagram

Phase 2 - Marrow Integration (Last 1.5 hours)

1. Go through the Marrow rapid revision cards for Neoplasia after reading each Robbins section
2. Marrow condenses the high-yield MCQ points Robbins expands on - use it to pick out what gets asked
3. Key Marrow topics to absolutely cover:
   • Oncogene vs TSG table (which gene, which cancer, mechanism)
   • Carcinogen-cancer associations (classic exam Q: Vinyl chloride → angiosarcoma)
   • Paraneoplastic syndromes table (which tumor → which syndrome → which mediator)
   • Tumor markers table
   • Translocation table (t9;22, t14;18, t8;14, t11;14, t15;17)

High-Yield MCQ Hotspots (USMLE/NEET PG Pattern)

Quick Reference: Key Translocations Table

---

Practical Tips for Tomorrow

1. Start at 8 AM - neoplasia is dense and needs a fresh brain.
2. Do NOT read the entire Robbins text linearly - use the outline above to navigate. Robbins has ~60 pages on this topic; you must selectively skip epidemiology prose.
3. After each major section, close the book and reproduce the mind map branch from memory - takes 2 min but locks it in.
4. Marrow question bank - after finishing Robbins, do Marrow's Neoplasia QBank immediately (same day). Aim for 60-80 questions. Review all explanations, not just wrong answers.
5. Revision hour: In the final 60 min, reproduce the full translocation table, paraneoplastic table, and tumor marker table from scratch on paper - these are the most-tested factual clusters.